Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $34.42

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $34.4167.

DYN has been the topic of a number of analyst reports. Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. Royal Bank Of Canada lifted their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. Morgan Stanley reduced their target price on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, August 17th.

Insider Activity

In other news, Director Jason P. Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares in the company, valued at approximately $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the transaction, the chief financial officer directly owned 121,563 shares in the company, valued at $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 4,139,196 shares of company stock worth $99,449,852 over the last ninety days. Insiders own 9.46% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors have recently bought and sold shares of the business. Creative Planning grew its holdings in Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares in the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics in the first quarter worth $26,000. Caxton Associates LLP raised its holdings in Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 0.1%

Shares of DYN opened at $26.36 on Friday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a 50-day moving average price of $24.13 and a two-hundred day moving average price of $19.96. The stock has a market cap of $4.92 billion, a price-to-earnings ratio of -7.92 and a beta of 1.07. Dyne Therapeutics has a 12 month low of $11.92 and a 12 month high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Equities analysts predict that Dyne Therapeutics will post -3.47 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.